

CSL Ltd (CSL) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/CA09B25782BEN.html
Date:	October 4, 2018
Pages:	56
Price:	US\$ 125.00
ID:	CA09B25782BEN

CSL Ltd (CSL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

CSL Ltd (CSL) carries out research and development, manufacturing, marketing and distribution of biopharmaceutical and related products. Its product portfolio include plasma-derived products for treating bleeding disorders such as hemophilia and von Willebrand disease, hereditary angioedema, primary and secondary immune deficiencies, inherited respiratory disease and neurological disorders; influenza vaccine; and protein-based medicines for treating serious human illnesses. The company also provides products to prevent hemolytic disease in newborns and infection in solid organ transplant recipients and to treat specific infections and help victims of trauma, shock and burns. CSL also markets an array of vaccines, anti-venoms and pharmaceutical products supplied by other manufacturers. The company offers its products in Australia, Germany, Switzerland, the UK, the US and rest of the world. CSL is headquartered in Parkville, Victoria, Australia.

CSL Ltd Key Recent Developments

Aug 15,2018: CSL Delivers a Full Year Net Profit of \$1.7 billion

Dec 13,2017: CSL Appoints New Directors

Dec 13,2017: Former CSL boss to return as chairman

Dec 11,2017: New national plasma agreement ensures supply for Australian patients

Dec 11,2017: CSL Behring Australia and National Blood Authority Sign New National Fractionation Agreement for Australia

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

CSL Ltd - Key Facts

CSL Ltd - Key Employees

CSL Ltd - Key Employee Biographies

CSL Ltd - Major Products and Services

CSL Ltd - History

CSL Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview

CSL Ltd - Business Description

Business Segment: CSL Behring

Overview

Performance

Business Segment: Seqirus

Overview

Performance

Geographical Segment: Australia

Performance

Geographical Segment: Germany

Performance

Geographical Segment: Rest of World

Performance

Geographical Segment: Switzerland

Performance

Geographical Segment: The UK

Performance

Geographical Segment: The US

Performance

R&D Overview

CSL Ltd - Corporate Strategy

CSL Ltd - SWOT Analysis

SWOT Analysis - Overview

CSL Ltd - Strengths

CSL Ltd - Weaknesses

CSL Ltd - Opportunities

CSL Ltd - Threats

CSL Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018

CSL Ltd, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Aug 15, 2018: CSL Delivers a Full Year Net Profit of \$1.7 billion

Dec 13, 2017: CSL Appoints New Directors

Dec 11, 2017: CSL Behring Australia and National Blood Authority Sign New National Fractionation Agreement for Australia

Dec 11, 2017: New national plasma agreement ensures supply for Australian patients

Dec 07, 2017: Expansion of CSL Biotech Facility Drives Advanced Manufacturing Growth and Creates

Victorian Jobs

Dec 07, 2017: Expansion of CSL Biotech Facility Drives Advanced Manufacturing Growth and Creates Victorian Jobs

Oct 17, 2017: Australian Scientists awarded \$2.5m to support ground-breaking medical research into cancer diagnostics and cardiovascular disease

Sep 13, 2017: Seqirus Donates Influenza Vaccine for Hurricane Harvey Relief in Texas

Sep 11, 2017: New Phase III Study Shows Significantly Greater Efficacy in Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine

Aug 16, 2017: CSL announces Full Year Result 2017

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

LIST OF TABLES

CSL Ltd, Key Facts

CSL Ltd, Key Employees

CSL Ltd, Key Employee Biographies

CSL Ltd, Major Products and Services

CSL Ltd, History

CSL Ltd, Other Locations

CSL Ltd, Subsidiaries

CSL Ltd, Key Competitors

CSL Ltd, Ratios based on current share price

CSL Ltd, Annual Ratios

CSL Ltd, Annual Ratios (Cont.1)

CSL Ltd, Annual Ratios (Cont.2)

CSL Ltd, Interim Ratios

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018

CSL Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

LIST OF FIGURES

CSL Ltd, Performance Chart (2014 - 2018)

CSL Ltd, Ratio Charts

CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

CSL Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Plasvacc Pty Ltd

Novita Healthcare Ltd
Novavax Inc
Merck & Co Inc
MedImmune LLC
GlaxoSmithKline Plc
Daiichi Sankyo Co Ltd
AstraZeneca Plc

I would like to order:

Product name: CSL Ltd (CSL) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/CA09B25782BEN.html>
Product ID: CA09B25782BEN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/CA09B25782BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**